Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA) price on Friday, May 23, rose 3.62% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $26.89.
A look at the stock’s price movement, the close in the last trading session was $25.95. Turning to its 52-week performance, $28.56 and $17.38 were the 52-week high and 52-week low respectively. Overall, KNSA moved 30.79% over the past month.
Kiniksa Pharmaceuticals International Plc’s market cap currently stands at around $1.96 billion, with investors looking forward to this quarter’s earnings report slated for in June.
Analysts have a consensus estimate of 145.22M for the company’s revenue for the quarter, with a low and high estimate of 139.58M and 148.21M respectively. The average forecast suggests up to a 33.68% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 599.62M, representing a 41.68% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that KNSA is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 1 recommend KNSA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
KNSA’s current price about 2.26% and 14.79% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 61.37, while 7-day volatility ratio is 2.44% and 4.79% in the 30-day chart. Further, Kiniksa Pharmaceuticals International Plc (KNSA) has a beta value of 0.04, and an average true range (ATR) of 1.07. Analysts have given the company’s stock an average 52-week price target of $35, forecast between a low of $34 and high of $40. Looking at the price targets, the low is -26.44% off current price level while to achieve the yearly target high, price needs to move -48.75%. Nonetheless, investors will most likely welcome a -30.16% jump to $35 which is the analysts’ median price.
If we refocus on Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA), historical trading data shows that trading volumes averaged 646.99K over the past 3 months. The company’s latest data on shares outstanding shows there are 42.16 million shares.
The 44.54% of Kiniksa Pharmaceuticals International Plc’s shares are in the hands of company insiders while institutional holders own 55.41% of the company’s shares. Current price change has pushed the stock 35.95% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the KNSA stock continues to rise going into the next quarter.
